Real-World Multicenter Experience with Mepolizumab and Benralizumab in the Treatment of Uncontrolled Severe Eosinophilic Asthma Over 12 Months
出版年份 2021 全文链接
标题
Real-World Multicenter Experience with Mepolizumab and Benralizumab in the Treatment of Uncontrolled Severe Eosinophilic Asthma Over 12 Months
作者
关键词
-
出版物
Journal of Asthma and Allergy
Volume Volume 14, Issue -, Pages 863-871
出版商
Informa UK Limited
发表日期
2021-07-12
DOI
10.2147/jaa.s319572
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Regulatory T cell monitoring in severe eosinophilic asthma patients treated with mepolizumab
- (2021) Laura Bergantini et al. SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on Benralizumab
- (2020) David J. Jackson et al. DRUG SAFETY
- Personalized Approach of Severe Eosinophilic Asthma Patients Treated with Mepolizumab and Benralizumab
- (2020) Laura Bergantini et al. INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY
- Mepolizumab and Benralizumab in Severe Eosinophilic Asthma: Preliminary Results of a Proteomic Study
- (2020) Lorenza Vantaggiato et al. LUNG
- Ceruloplasmin and oxidative stress in severe eosinophilic asthma patients treated with Mepolizumab and Benralizumab
- (2020) Claudia Landi et al. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
- Indirect treatment comparisons and biologics
- (2019) David Mauger et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- The prevalence and disease burden of severe eosinophilic asthma in Japan
- (2019) Tadao Nagasaki et al. JOURNAL OF ASTHMA
- The Cytokines of Asthma
- (2019) Bart N. Lambrecht et al. IMMUNITY
- Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement
- (2019) Brian L. Graham et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Anti-IL-5 therapy in patients with severe eosinophilic asthma – clinical efficacy and possible criteria for treatment response
- (2018) Nora Drick et al. BMC Pulmonary Medicine
- Severe Asthma
- (2018) Marek Lommatzsch et al. Deutsches Arzteblatt International
- Anti–IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison
- (2018) William Busse et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Reslizumab Compared with Benralizumab in Patients with Eosinophilic Asthma: A Systematic Literature Review and Network Meta-Analysis
- (2018) Thomas B. Casale et al. Journal of Allergy and Clinical Immunology-In Practice
- Matching-adjusted indirect comparison of benralizumab versus interleukin-5 inhibitors for the treatment of severe asthma: a systematic review
- (2018) Arnaud Bourdin et al. EUROPEAN RESPIRATORY JOURNAL
- Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial
- (2018) William W Busse et al. Lancet Respiratory Medicine
- Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies
- (2017) Frank C. Albers et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population
- (2017) Marjan Kerkhof et al. THORAX
- Overlap of atopic, eosinophilic, and TH2-high asthma phenotypes in a general population with current asthma
- (2016) Trung N. Tran et al. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
- Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels
- (2016) Leif Bjermer et al. CHEST
- Comparison of anti-interleukin-5 therapies in patients with severe asthma: global and indirect meta-analyses of randomized placebo-controlled trials
- (2016) Y. Cabon et al. CLINICAL AND EXPERIMENTAL ALLERGY
- Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial
- (2016) Eugene R Bleecker et al. LANCET
- Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial
- (2016) J Mark FitzGerald et al. LANCET
- Economic Burden of Illness Among Patients with Severe Asthma in a Managed Care Setting
- (2016) Benjamin Chastek et al. Journal of Managed Care & Specialty Pharmacy
- Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma
- (2014) Elisabeth H. Bel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma
- (2014) Hector G. Ortega et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prospective evaluation of current asthma control using ACQ and ACT compared with GINA criteria
- (2011) Stephanie Korn et al. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
- Lung damage and airway remodelling in severe asthma
- (2011) C. E. Brightling et al. CLINICAL AND EXPERIMENTAL ALLERGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started